recombinant human vegfr1 flt 1 fc chimera protein (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
94
Structured Review
R&D Systems
recombinant human vegfr1 flt 1 fc chimera protein
Recombinant Human Vegfr1 Flt 1 Fc Chimera Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 33 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fc+chimera/Recombinant+Human+VEGFR1%2FFlt-1+Fc+Chimera+Protein/pmc13059125-197-3-9
Average 94 stars, based on 33 article reviews
Recombinant Human Vegfr1 Flt 1 Fc Chimera Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 33 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fc+chimera/Recombinant+Human+VEGFR1%2FFlt-1+Fc+Chimera+Protein/pmc13059125-197-3-9
Average 94 stars, based on 33 article reviews
recombinant human vegfr1 flt 1 fc chimera protein - by Bioz Stars,
2026-09
94/100 stars
Images
Related Articles
Recombinant:Article Title: A pilot study on nitration/dysfunction of NK1 segment of myogenic stem cell activator HGF. Article Snippet: Monoclonal anti-BrdU (clone G3G4) and anti-desmin antibodies (clone D3) were from Developmental Studies Hybridoma Bank (Iowa City, IA, USA). .. Article Title: Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells. Article Snippet: From the *Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany †Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Germany Address correspondence to: Sebastian Zundler, MD, PhD, Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-Universität ErlangenNürnberg, Ulmenweg 18, D-91054 Erlangen, Germany (sebastian.zundler@uk-erlangen.de). Article Title: Design, synthesis, and LFA-1/ICAM-1 antagonist activity evaluation of Lifitegrast analogues Article Snippet: .. Labeled cells were incubated in 70 μL of assay medium in each well of a 96-well plate at 5 × 10 5 cells per well with 70 μL of compound or the positive control in assay medium at 37 °C for 30 min. A 100 μL aliquot of this fluorescence-labeled Jurkat cell suspension was allowed to settle in the presence of compound or the positive control in wells of a 96-well plate coated with recombinant human ICAM-1 expressed as an Article Title: Myeloid Poldip2 Contributes to the Development of Pulmonary Inflammation by Regulating Neutrophil Adhesion in a Murine Model of Acute Respiratory Distress Syndrome Article Snippet: .. Soluble ICAM- 1 Binding Assay The soluble ICAM- 1 binding assay was used to assess beta integrin activation in neutrophils.26 Bone marrow cells isolated from myePoldip2+/+ and myePoldip2- /- mice were exposed to 2 mmol/L EDTA (as negative control), 5 mmol/L MnCl2 or an equal volume of HBSS+, in the presence of 10 μg/mL recombinant mouse ICAM- 1- Article Title: Chronic stimulation desensitizes β2-adrenergic receptor responses in natural killer cells. Article Snippet: When indicated, the cells were additionally treated with inhibitors (10 μM H89 [Cayman Chemicals] or 25 μM ESI09 [TOCRIS]). .. In restimulation experiments, inhibitors (10 μM H89 or Barbadin 50 μM [MedChemExpress]) were kept in media for 24 h and were washed away before LC-AA and second β2AR stimulation. xCELLigence-based detachment assay E-plates were coated with 7 ng/mL goat anti-mouse antibody (Dianova) followed by 2 ng/mL of recombinant human ICAM-1– Article Title: Supporting information Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye Article Snippet: .. Labeled cells were incubated in 70 μL of assay medium in each well of a 96- well plate at 500,000 cells per well with 70 μL of SAR 1118 or the positive control in assay medium at 37 °C for 30 min. A 100 μL aliquot of this fluorescence-labeled Jurkat cell suspension was allowed to settle in the presence of SAR 1118 or the positive control in wells of a 96-well plate coated with recombinant human ICAM-1 expressed as an Article Title: Expression and function of α4β7 integrin predict the success of vedolizumab treatment in inflammatory bowel disease. Article Snippet: Inflammatory bowel diseases are medically intractable and require constant therapy in many cases.. While a growing number of biologicals and small molecules is available for treatment, a substantial portion of patients experiences primary non-response to these compounds and head-to-head evidence for therapy selection is scarce.. Thus, approaches to predict treatment success in individual patients are a huge unmet need. Affinity Purification:Article Title: A pilot study on nitration/dysfunction of NK1 segment of myogenic stem cell activator HGF. Article Snippet: Monoclonal anti-BrdU (clone G3G4) and anti-desmin antibodies (clone D3) were from Developmental Studies Hybridoma Bank (Iowa City, IA, USA). .. Concentration Assay:Article Title: Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells. Article Snippet: From the *Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany †Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Germany Address correspondence to: Sebastian Zundler, MD, PhD, Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-Universität ErlangenNürnberg, Ulmenweg 18, D-91054 Erlangen, Germany (sebastian.zundler@uk-erlangen.de). Saline:Article Title: Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells. Article Snippet: From the *Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany †Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Germany Address correspondence to: Sebastian Zundler, MD, PhD, Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-Universität ErlangenNürnberg, Ulmenweg 18, D-91054 Erlangen, Germany (sebastian.zundler@uk-erlangen.de). other:Article Title: The Effects of Preeclamptic Milieu on Cord Blood Derived Endothelial Colony-Forming Cells Article Snippet: ECFCs and PRECs were treated with 5 nM Labeling:Article Title: Design, synthesis, and LFA-1/ICAM-1 antagonist activity evaluation of Lifitegrast analogues Article Snippet: .. Labeled cells were incubated in 70 μL of assay medium in each well of a 96-well plate at 5 × 10 5 cells per well with 70 μL of compound or the positive control in assay medium at 37 °C for 30 min. A 100 μL aliquot of this fluorescence-labeled Jurkat cell suspension was allowed to settle in the presence of compound or the positive control in wells of a 96-well plate coated with recombinant human ICAM-1 expressed as an Article Title: Supporting information Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye Article Snippet: .. Labeled cells were incubated in 70 μL of assay medium in each well of a 96- well plate at 500,000 cells per well with 70 μL of SAR 1118 or the positive control in assay medium at 37 °C for 30 min. A 100 μL aliquot of this fluorescence-labeled Jurkat cell suspension was allowed to settle in the presence of SAR 1118 or the positive control in wells of a 96-well plate coated with recombinant human ICAM-1 expressed as an Incubation:Article Title: Design, synthesis, and LFA-1/ICAM-1 antagonist activity evaluation of Lifitegrast analogues Article Snippet: .. Labeled cells were incubated in 70 μL of assay medium in each well of a 96-well plate at 5 × 10 5 cells per well with 70 μL of compound or the positive control in assay medium at 37 °C for 30 min. A 100 μL aliquot of this fluorescence-labeled Jurkat cell suspension was allowed to settle in the presence of compound or the positive control in wells of a 96-well plate coated with recombinant human ICAM-1 expressed as an Article Title: Supporting information Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye Article Snippet: .. Labeled cells were incubated in 70 μL of assay medium in each well of a 96- well plate at 500,000 cells per well with 70 μL of SAR 1118 or the positive control in assay medium at 37 °C for 30 min. A 100 μL aliquot of this fluorescence-labeled Jurkat cell suspension was allowed to settle in the presence of SAR 1118 or the positive control in wells of a 96-well plate coated with recombinant human ICAM-1 expressed as an Positive Control:Article Title: Design, synthesis, and LFA-1/ICAM-1 antagonist activity evaluation of Lifitegrast analogues Article Snippet: .. Labeled cells were incubated in 70 μL of assay medium in each well of a 96-well plate at 5 × 10 5 cells per well with 70 μL of compound or the positive control in assay medium at 37 °C for 30 min. A 100 μL aliquot of this fluorescence-labeled Jurkat cell suspension was allowed to settle in the presence of compound or the positive control in wells of a 96-well plate coated with recombinant human ICAM-1 expressed as an Article Title: Supporting information Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye Article Snippet: .. Labeled cells were incubated in 70 μL of assay medium in each well of a 96- well plate at 500,000 cells per well with 70 μL of SAR 1118 or the positive control in assay medium at 37 °C for 30 min. A 100 μL aliquot of this fluorescence-labeled Jurkat cell suspension was allowed to settle in the presence of SAR 1118 or the positive control in wells of a 96-well plate coated with recombinant human ICAM-1 expressed as an Fluorescence:Article Title: Design, synthesis, and LFA-1/ICAM-1 antagonist activity evaluation of Lifitegrast analogues Article Snippet: .. Labeled cells were incubated in 70 μL of assay medium in each well of a 96-well plate at 5 × 10 5 cells per well with 70 μL of compound or the positive control in assay medium at 37 °C for 30 min. A 100 μL aliquot of this fluorescence-labeled Jurkat cell suspension was allowed to settle in the presence of compound or the positive control in wells of a 96-well plate coated with recombinant human ICAM-1 expressed as an Article Title: Supporting information Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye Article Snippet: .. Labeled cells were incubated in 70 μL of assay medium in each well of a 96- well plate at 500,000 cells per well with 70 μL of SAR 1118 or the positive control in assay medium at 37 °C for 30 min. A 100 μL aliquot of this fluorescence-labeled Jurkat cell suspension was allowed to settle in the presence of SAR 1118 or the positive control in wells of a 96-well plate coated with recombinant human ICAM-1 expressed as an Suspension:Article Title: Design, synthesis, and LFA-1/ICAM-1 antagonist activity evaluation of Lifitegrast analogues Article Snippet: .. Labeled cells were incubated in 70 μL of assay medium in each well of a 96-well plate at 5 × 10 5 cells per well with 70 μL of compound or the positive control in assay medium at 37 °C for 30 min. A 100 μL aliquot of this fluorescence-labeled Jurkat cell suspension was allowed to settle in the presence of compound or the positive control in wells of a 96-well plate coated with recombinant human ICAM-1 expressed as an Article Title: Supporting information Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye Article Snippet: .. Labeled cells were incubated in 70 μL of assay medium in each well of a 96- well plate at 500,000 cells per well with 70 μL of SAR 1118 or the positive control in assay medium at 37 °C for 30 min. A 100 μL aliquot of this fluorescence-labeled Jurkat cell suspension was allowed to settle in the presence of SAR 1118 or the positive control in wells of a 96-well plate coated with recombinant human ICAM-1 expressed as an Titration:Article Title: Design, synthesis, and LFA-1/ICAM-1 antagonist activity evaluation of Lifitegrast analogues Article Snippet: .. Labeled cells were incubated in 70 μL of assay medium in each well of a 96-well plate at 5 × 10 5 cells per well with 70 μL of compound or the positive control in assay medium at 37 °C for 30 min. A 100 μL aliquot of this fluorescence-labeled Jurkat cell suspension was allowed to settle in the presence of compound or the positive control in wells of a 96-well plate coated with recombinant human ICAM-1 expressed as an Binding Assay:Article Title: Myeloid Poldip2 Contributes to the Development of Pulmonary Inflammation by Regulating Neutrophil Adhesion in a Murine Model of Acute Respiratory Distress Syndrome Article Snippet: .. Soluble ICAM- 1 Binding Assay The soluble ICAM- 1 binding assay was used to assess beta integrin activation in neutrophils.26 Bone marrow cells isolated from myePoldip2+/+ and myePoldip2- /- mice were exposed to 2 mmol/L EDTA (as negative control), 5 mmol/L MnCl2 or an equal volume of HBSS+, in the presence of 10 μg/mL recombinant mouse ICAM- 1- Activation Assay:Article Title: Myeloid Poldip2 Contributes to the Development of Pulmonary Inflammation by Regulating Neutrophil Adhesion in a Murine Model of Acute Respiratory Distress Syndrome Article Snippet: .. Soluble ICAM- 1 Binding Assay The soluble ICAM- 1 binding assay was used to assess beta integrin activation in neutrophils.26 Bone marrow cells isolated from myePoldip2+/+ and myePoldip2- /- mice were exposed to 2 mmol/L EDTA (as negative control), 5 mmol/L MnCl2 or an equal volume of HBSS+, in the presence of 10 μg/mL recombinant mouse ICAM- 1- Isolation:Article Title: Myeloid Poldip2 Contributes to the Development of Pulmonary Inflammation by Regulating Neutrophil Adhesion in a Murine Model of Acute Respiratory Distress Syndrome Article Snippet: .. Soluble ICAM- 1 Binding Assay The soluble ICAM- 1 binding assay was used to assess beta integrin activation in neutrophils.26 Bone marrow cells isolated from myePoldip2+/+ and myePoldip2- /- mice were exposed to 2 mmol/L EDTA (as negative control), 5 mmol/L MnCl2 or an equal volume of HBSS+, in the presence of 10 μg/mL recombinant mouse ICAM- 1- Negative Control:Article Title: Myeloid Poldip2 Contributes to the Development of Pulmonary Inflammation by Regulating Neutrophil Adhesion in a Murine Model of Acute Respiratory Distress Syndrome Article Snippet: .. Soluble ICAM- 1 Binding Assay The soluble ICAM- 1 binding assay was used to assess beta integrin activation in neutrophils.26 Bone marrow cells isolated from myePoldip2+/+ and myePoldip2- /- mice were exposed to 2 mmol/L EDTA (as negative control), 5 mmol/L MnCl2 or an equal volume of HBSS+, in the presence of 10 μg/mL recombinant mouse ICAM- 1- Control:Article Title: Expression and function of α4β7 integrin predict the success of vedolizumab treatment in inflammatory bowel disease. Article Snippet: Inflammatory bowel diseases are medically intractable and require constant therapy in many cases.. While a growing number of biologicals and small molecules is available for treatment, a substantial portion of patients experiences primary non-response to these compounds and head-to-head evidence for therapy selection is scarce.. Thus, approaches to predict treatment success in individual patients are a huge unmet need. |